|
Home > Abstracts, News & Events
Levine RL, McCollum D, Hursting MJ. Venous
Thromboembolism in Heparin-Treated Patients: How Frequently Is It Associated
With Heparin-Induced Thrombocytopenia?
Journal of Thrombosis and Haemostasis, Volume 3, Supplement
1, Abstract P1515, 2005.
Lewis BE, Wallis DE, Hursting MJ, Levine RL, Fareed J, Katz E, McCollum D. Effects
of the Direct Thrombin Inhibitor Argatroban, Demographic Variables, and Platelet
Count on Thrombotic Risks in Heparin-Induced Thrombocytopenia.
Journal of Thrombosis and Haemostasis, Volume 3, Supplement
1, Abstract P0547, 2005.
Begelman SM, Hursting MJ, Aghababian RV, McCollum D. Heparin-Induced Thrombocytopenia From Venous Thromboembolism Treatment. Session Type: Poster Session 66-I.
Blood, Volume 106, Issue 11, Abstract 908, November 16, 2005.
Lo GK, Warkentin TE. Towards a Conceptual Framework for Diagnosis of Heparin-Induced Thrombocytopenia (HIT). Session Type: Poster Session 392-I.
Blood, Volume 106, Issue 11, Abstract 1234, November 16, 2005.
Frame JN, Lambert A, Davis EA, Wang Y, Emmett MS. Delayed-Onset Heparin-Induced Thrombocytopenia and/or Thrombosis Following Open Heart Surgery Hospital Discharge. Session Type: Poster Session 397-I.
Blood, Volume 106, Issue 11, Abstract 1239, November 16, 2005.
Pouplard C, Fouassier M, Ternisien C, Gueret P, Trossaert M, Regina S, Gruel Y. Prospective Evaluation of 4T's Score and Rapid Particle Gel Immuno-Assay Specific to H/PF4 Complexes to Exclude Heparin-Induced Thrombocytopenia. Session Type: Poster Session 402-I.
Blood, Volume 106, Issue 11, Abstract 1244, November 16, 2005.
Streiff MB, Kickler TS, Weir EG. Does the Platelet Factor 4 (PF4) ELISA Correlate With the Clinical Diagnosis of Type II Heparin-Induced Thrombocytopenia? Session Type: Poster Session 383-II.
Blood, Volume 106, Issue 11, Abstract 2179, November 16, 2005.
Davis EA, Frame JN, Wang Y, Reed J. Evaluating the Outcomes of Quality Improvement Initiatives of a Multi-Disciplinary Heparin-Induced Thrombocytopenia (HIT) Task Force. Session Type: Poster Session 456-II.
Blood, Volume 106, Issue 11, Abstract 2252, November 16, 2005.
Hursting MJ, McCollum D, Levine RL. How Frequently Is Venous Thromboembolism in Heparin-Treated Patients Associated With Heparin-Induced Thrombocytopenia? Session Type: Poster Session 269-III.
Blood, Volume 106, Issue 11, Abstract 3018, November 16, 2005.
Frame JN, Davis EA, Wang Y, Emmett MS, Malapur AR. Multiple Organ Failure Syndrome Complicating Heparin-Induced Thrombocytopenia. Session Type: Poster Session 272-III.
Blood, Volume 106, Issue 11, Abstract 3021, November 16, 2005.
Smythe MA, Koerber JM, Mattson JC. Capturing the Financial Impact of Heparin-Induced Thrombocytopenia. Session Type: Poster Session 378-III.
Blood, Volume 106, Issue 11, Abstract 3127, November 16, 2005.
Hergenroeder GW, Francis JL, Miller CC III, Levine RL. Prevalence of Heparin Antibodies in ICU Patients (The HAICU Study). Session Type: Publication Only.
Blood, Volume 106, Issue 11, Abstract 4011, November 16, 2005.
Lakey MA, Arndt DW, Marques MB. Repeat Borderline or Negative Platelet Factor-4 ELISA May Yield Positive Results in Patients With Clinical Suspicion of Heparin-Induced Thrombocytopenia. Session Type: Publication Only.
Blood, Volume 106, Issue 11, Abstract 4014, November 16, 2005.
Carrier M, Knoll G, Kovacs M, Rodger MA. High Prevalence of Antibodies to the Heparin-Platelet Factor 4 Complex in Hemodialysis Patients. Session Type: Publication Only.
Blood, Volume 106, Issue 11, Abstract 4119, November 16, 2005.
Important Safety Information
As with all anticoagulants, bleeding is a serious concern. Argatroban is contraindicated in patients with overt major bleeding or those with hypersensitivity to the product or any of its components. Argatroban should be used with extreme caution in disease states or other circumstances in which there is an increased risk of hemorrhage. Overall major bleeding was reported in 5.3% of Argatroban-treated patients with HIT versus 6.7% of the historical controls. Overall major bleeding was reported in 1.8% of Argatroban-treated patients undergoing PCI versus 3.1% of the historical controls. Intracranial bleeding was not observed in the 568 patients treated with Argatroban for HIT (with or without thrombosis) or in the 91 patients who underwent PCI. The most common nonhemorrhagic side effects in HIT patients, regardless of the relationship to treatment, were dyspnea, hypotension, and fever. In patients undergoing PCI, the nonhemorrhagic side effects, regardless of the relationship to treatment, included chest pain, hypotension, and back pain. Please see full Prescribing Information for additional safety information on Argatroban.
Disclaimer
The Argatroban.com Web site contains links to third-party
Web sites on the Internet. These links are provided as a service to individuals
interested in more information in HIT. These sites are not part of this
GlaxoSmithKline (GSK) Web site. The content and materials in these third-party
Web sites are not produced or endorsed by GSK and may refer to uses of our
products that are not recommended by GSK.
|
